Opinion
Volume 09:03, 2024

Journal of Inflammatory Bowel Diseases & Disorders

ISSN: 2476-1958 Open Access

Infliximab and the Microbiome: Exploring the Link between Biologic Treatment and Gut Health

Mohnader Abadi*

Department of Radiopharmacy, Tehran University of Medical Sciences, Tehran, Iran

Introduction

The human gut microbiome, composed of trillions of microorganisms including bacteria, fungi, and viruses, plays a crucial role in maintaining the overall health of the Gastrointestinal (GI) tract and supporting immune system function. In recent years, there has been growing recognition of the importance of the gut microbiome in both the pathogenesis and treatment of various inflammatory diseases. In particular, autoimmune diseases such as Inflammatory Bowel Disease (IBD), rheumatoid arthritis, and ankylosing spondylitis have been found to have strong associations with dysbiosis (an imbalance in the microbiome), which can exacerbate inflammation and immune system dysfunction.

Infliximab, a biologic therapy that inhibits Tumor Necrosis Factor-Alpha (TNF-α), has become a cornerstone in the treatment of a range of inflammatory conditions, including Crohn's disease, ulcerative colitis, ankylosing spondylitis, and rheumatoid arthritis. While the clinical efficacy of infliximab in controlling inflammation and alleviating symptoms is well-documented, its impact on the gut microbiome remains an area of active research. Infliximab's immunosuppressive effects may potentially alter the composition of the gut microbiota, leading to changes in microbial diversity and abundance that could either promote therapeutic benefits or give rise to adverse outcomes. This article explores the current understanding of the relationship between infliximab therapy and the gut microbiome, examining how this biologic treatment might influence gut health and its broader implications for patient care, particularly in patients with gastrointestinal autoimmune diseases [1].

Description

The gut microbiome is integral to the development and function of the immune system. It helps in the development of mucosal immunity, promotes the production of anti-inflammatory cytokines, and prevents excessive immune responses to commensal microbes and food antigens. The microbiome contributes to the integrity of the intestinal mucosal barrier, which prevents the entry of pathogens and toxins into the bloodstream while allowing the absorption of nutrients. Gut bacteria assist in the fermentation of dietary fibers and the synthesis of essential vitamins and nutrients, including certain B vitamins and short-chain fatty acids, which have anti-inflammatory properties. Dysbiosis, or an imbalance in the gut microbiome, has been linked to the development and exacerbation of several autoimmune diseases. In conditions like Crohn's disease, ulcerative colitis, and rheumatoid arthritis, altered microbiome composition can lead to heightened inflammation and immune system dysfunction.

***Address for Correspondence:** Mohnader Abadi, Department of Radiopharmacy, Tehran University of Medical Sciences, Tehran, Iran; E-mail: mohndar.abdi@Wgmail.com*

Received: 01 August, 2024, Manuscript No. jibdd-24-153443; **Editor assigned:** 03 August, 2024, Pre QC No. P-153443; **Reviewed:** 17 August, 2024, QC No. Q-153443; **Revised:** 23 August, 2024, Manuscript No. R-153443; **Published:** 30 August, 2024, DOI: 10.37421/2476-1958.2024.9.219

Infliximab is a monoclonal antibody that targets and neutralizes TNF-α, a cytokine that plays a pivotal role in the inflammatory processes associated with autoimmune diseases. By inhibiting TNF-α, infliximab reduces the production of other pro-inflammatory cytokines and prevents the recruitment of immune cells to sites of inflammation, leading to the suppression of disease activity and clinical symptoms [2]. In diseases like IBD and rheumatoid arthritis, infliximab can significantly reduce intestinal and systemic inflammation, improve patient quality of life, and prevent long-term joint and tissue damage. However, TNF-α also plays an important role in the regulation of the gut microbiome and immune responses in the intestines. As such, inhibiting TNF-α with infliximab may have significant implications for the gut microbiota, which is still an area of investigation. Some studies suggest that TNF-α inhibition may influence the balance of microbial communities in the intestines, potentially either contributing to or mitigating dysbiosis. Research exploring the effects of infliximab on the gut microbiome is still in its early stages, but several studies have provided valuable insights. One of the most consistent findings is that infliximab therapy may lead to changes in the diversity of the gut microbiome. A reduced microbial diversity is often seen in patients with chronic inflammatory conditions like IBD, and infliximab treatment has been associated with modest changes in the microbial populations.

Some studies report a decrease in the abundance of certain bacterial species that are typically present in healthy individuals, while others observe an increase in the growth of beneficial bacteria, such as Firmicutes and Bacteroidetes, which are known for their anti-inflammatory properties. Infliximab's ability to reduce intestinal inflammation in patients with IBD may be linked to its effect on the gut microbiome. By suppressing TNF-α, infliximab may help restore a more balanced microbial environment, which in turn supports mucosal healing and reinforces the intestinal barrier function. The modulation of the microbiome may also reduce the incidence of secondary infections and opportunistic pathogens, which are more common in individuals with dysbiosis.

Some studies have shown that while infliximab can improve clinical outcomes in IBD patients, it may also exacerbate dysbiosis in some cases. For instance, the use of infliximab has been associated with an overgrowth of pathogenic microbes, such as Clostridium difficile, which can lead to antibiotic-resistant infections and further compromise gut health. Additionally, the suppression of TNF-α could reduce the body's natural ability to respond to infections, including those caused by gut microbes. Infliximab's ability to restore mucosal integrity in patients with IBD may also contribute to positive changes in the microbiome [3]. The healing of intestinal lesions and the re-establishment of the epithelial barrier can reduce microbial translocation (the passage of microbes into the bloodstream) and prevent excessive immune activation. This creates a more favorable environment for beneficial gut bacteria to thrive, while limiting the overgrowth of harmful microbes.

The long-term effects of infliximab on the gut microbiome remain unclear. Some studies have suggested that the impact of TNF-α inhibitors on the microbiome may be transient, with the microbiota returning to its pre-treatment state after therapy cessation. Moreover, the response to infliximab can vary widely among individuals, which underscores the importance of personalized treatment strategies that consider a patient's microbiome composition. Understanding the relationship between infliximab and the gut microbiome has important implications for improving the safety and efficacy of biologic therapies. By monitoring changes in the microbiome during treatment, clinicians may be able [4]. Regular microbiome profiling could help identify

patients at risk for developing dysbiosis and associated complications, such as infections or disease flare-ups. Early intervention with probiotics, dietary modifications, or adjustments in biologic therapy may help mitigate these risks.

Knowledge of the microbiome's role in treatment response could enable more tailored biologic therapies. In the future, microbiome-based biomarkers may guide clinicians in selecting the most appropriate therapy for each patient, reducing trial-and-error approaches. Further research is needed to determine the long-term effects of infliximab on the gut microbiome and the potential for development of antibiotic-resistant infections or other adverse outcomes. It is essential to balance the therapeutic benefits of TNF-α inhibition with the risks of altering the microbiome in ways that could undermine overall health [5].

Conclusion

Infliximab has revolutionized the treatment of autoimmune diseases, particularly in conditions such as IBD, rheumatoid arthritis, and ankylosing spondylitis. While the immunosuppressive effects of infliximab are well-established in reducing inflammation and improving clinical outcomes, its impact on the gut microbiome represents an emerging area of research. Infliximab may alter the diversity and composition of the gut microbiota, with potential benefits such as improved mucosal healing and reduced disease activity, as well as risks, including the development of dysbiosis and increased susceptibility to infections.

As our understanding of the complex relationship between biologic therapies like infliximab and the gut microbiome continues to evolve, it will become increasingly important to consider the microbiome as part of the treatment strategy for autoimmune diseases. Future research should focus on elucidating the long-term effects of infliximab on gut health, identifying potential microbial biomarkers for treatment response, and developing strategies to minimize the risks associated with microbial imbalances. Through these efforts, we can optimize the use of infliximab and other biologics, improving both clinical outcomes and the overall health of patients.

Acknowledgment

None.

Conflict of Interest

None.

References

1. Pickard, Joseph M., Melody Y. Zeng, Roberta Caruso and Gabriel Núñez. "Gut microbiota: Role in pathogen colonization, immune responses and inflammatory disease." *Immunol Rev* 279 (2017): 70-89.
2. Groschwitz, Katherine R. and Simon P. Hogan. "Intestinal barrier function: Molecular regulation and disease pathogenesis." *J Allergy Clin Immunol* 124 (2009): 3-20.
3. Martini, Eva, Susanne M. Krug, Britta Siegmund and Markus F. Neurath, et al. "Mend your fences: The epithelial barrier and its relationship with mucosal immunity in inflammatory bowel disease." *Cell Mol Gastroenterol Hepatol* 4 (2017): 33-46.
4. Gitter, Alfred H., Friederike Wullstein, Michael Fromm and Jörg Dieter Schulzke. "Epithelial barrier defects in ulcerative colitis: Characterization and quantification by electrophysiological imaging." *Gastroenterology* 121 (2001): 1320-1328.
5. Van der Sluis, Maria, Barbara AE De Koning, Adrianus CJM De Bruijn and Anna Velcich, et al. "Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection." *Gastroenterology* 131 (2006): 117-129.

How to cite this article: Abadi, Mohnader. "Infliximab and the Microbiome: Exploring the Link between Biologic Treatment and Gut Health." *J Inflamm Bowel Dis* 9 (2024): 219.